Deferasirox

Таблетки By prescription

An oral chelator whose primary use is to reduce chronic iron overload in patients receiving long-term blood transfusions for conditions such as beta-thalassaemia and other chronic anaemias.

Deferasirox

Important

The active substance of the drug Deferasirox is Deferasirox, which belongs to the pharmacotherapeutic group called: "Complexing agents". Patients with various forms of anaemia (e.g. thalassaemia, sickle cell anaemia or myelodysplastic syndrome) may require repeated blood transfusions, which may be the cause of excessive iron levels in the body. The reason for this is that the blood contains iron and the body does not have a natural mechanism for excreting the excess iron you get from blood transfusions. Patients with thalassaemia syndromes that are not dependent on blood transfusions can also develop iron overload over time, mainly related to increased iron absorption from food in response to low blood cell counts. Over time, iron overload can cause damage to important organs such as the liver and heart. The drug Deferasirox is able to chelate (bind) iron ions and thereby reduce excess iron in the body (this condition is called iron overload). Carefully follow all instructions given by your doctor. They may differ from the general information given in the package insert.

Indications

The drug Deferasirox is intended for oral administration and is indicated for the prevention and treatment of:
- chronic post-transfusion iron overload in adults and children aged 2 years and older;
- chronic non-transfusion iron overload in patients with thalassaemia aged 10 years and older.
If there is no improvement or you (or your child) feel worsening, you should contact your doctor immediately.

Contraindications

Do not use Deferasirox:
- If you are allergic to deferasirox or any other components of the medicine (listed in section 6 of the leaflet insert);
- if you have a creatinine clearance (CK) <60 ml/min or a serum creatinine concentration 2 or more times the upper limit of the age-standardised range;
- if you have high-risk myelodysplastic syndrome or other haemoblastosis and non-haematological malignancies in which chelation therapy will be ineffective due to rapid disease progression;
- If you have severe liver function impairment (Child-Pugh class C);
- If you are pregnant or breastfeeding;
- if your child is less than 2 years old (no experience of use).
If you think any of these apply to you or your child, tell your doctor.

Usage

Always take the drug in full compliance with the recommendations of your doctor. If in doubt, consult your doctor. The recommended dose of Deferasirox for all patients is based on body weight. Your doctor will calculate the dose you need and tell you how many tablets you should take each day.
- 20 mg/kg body weight for patients with chronic post-transfusion iron overload;
- 10 mg/kg body weight for patients with thalassaemia and chronic non-transfusion iron overload.
Depending on your individual needs and response to treatment, your doctor may recommend a higher or lower starting dose and adjust the dose subsequently.
The maximum recommended daily dose is:
- 40 mg/kg body weight for patients with chronic post-transfusion iron overload;
- 20 mg/kg body weight for thalassaemic patients with chronic non-transfusion iron overload;
- 10 mg/kg body weight for patients with serum ferritin concentration <2000 µg/L without liver iron determination in chronic non-transfusion iron overload.
When switching from deferoxamine or deferasirox therapy in another dosage form to Deferasirox, dispersible tablets, a dose adjustment should be made, for this purpose consult your physician. Only the attending physician can select the correct dose of the drug Deferasirox.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.